In late September, Aegros employees received a memo asking them to ensure their personal email addresses were up-to-date in the work system because they were about to lose access to their corporate accounts.
At most companies, this would come as a surprise. But Aegros, a blood plasma start-up hoping to rival ASX-listed giant CSL, had struggled to make payroll on time for much of the year. This was just another irritation.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。